The HTRA1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human cell line, designed for loss-of-function studies of the HTRA1 serine protease gene. This genetically heterogeneous pool enables robust functional genomics research by disrupting the target gene, providing a versatile model for analyzing HTRA1-dependent signaling without the need for clonal isolation. The polyclonal format supports population-level analyses while minimizing the risk of clonal artifacts, making it suitable for a range of screening and mechanistic studies.
The HAP1 host cell line is a near-haploid human cell line originating from the KBM-7 chronic myeloid leukemia background, widely employed for genetic screening and knockout investigations. Its haploid complement facilitates efficient gene editing and simplifies the interpretation of knockout phenotypes, particularly in the context of leukemic cell models. HAP1 cells retain key signaling pathways relevant to hematopoietic malignancies, offering a physiologically relevant platform for studying cancer-associated genes.
HTRA1 encodes a secreted serine protease that acts as a critical negative regulator of transforming growth factor-beta (TGF-??) signaling and extracellular matrix (ECM) remodeling. The protease cleaves TGF-?? ligands and other substrates such as fibronectin, thereby attenuating signaling through TGFBR1/TGFBR2 receptor complexes and downstream SMAD2/3 phosphorylation. HTRA1 expression is induced by TGF-??, oxidative stress, and NF-??B, establishing a negative feedback loop that also intersects with bone morphogenetic protein (BMP) signaling components like BMPR1. Additionally, HTRA1 interacts with modulators including clusterin and serine protease inhibitors to fine-tune its proteolytic activity, positioning it at a nexus of pathways controlling cell growth, apoptosis, and ECM dynamics.
In the HAP1 leukemic background, disruption of HTRA1 is expected to relieve the protease??s inhibitory constraint on TGF-?? and BMP cascades, leading to enhanced signaling that can influence proliferation and survival. This model is particularly relevant for dissecting HTRA1??s tumor-suppressive roles in leukemia and other cancers, as well as its involvement in age-related macular degeneration and cerebral small vessel disease (CARASIL). The polyclonal knockout population thus provides a powerful tool for exploring context-dependent functions of HTRA1 in hematological and solid tumor settings.
Researchers can employ this polyclonal knockout cell population for a diverse array of applications, including functional genomics screens, TGF-?? signaling studies, and cancer research. Representative assays include western blotting for HTRA1 and phospho-SMAD2 to confirm pathway activation, RT-qPCR analysis of TGF-?? target genes, cell migration and apoptosis assays, and TGF-??-responsive reporter assays. The cells also serve as a valuable resource for drug screening campaigns aimed at modulating TGF-?? signaling in leukemia models. For further details, please contact Ascent Research.
